Fraud Investigation: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) on Behalf of Shareholders
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws. What Happened? On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension...
2026-01-26 12:24 AM EST
Levi & Korsinsky Launches Fraud Investigation on Behalf of Bgin Blockchain Limited (BGIN) Shareholders
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Bgin Blockchain Limited ("Bgin Blockchain Limited") (NASDAQ: BGIN) concerning potential violations of the federal securities laws. Bgin released unaudited financial results on November 14, 2025, for the six months ended June 30, 2025, revealing that total revenue had declined roughly $96 million from the previous year, operating expenses increased 582.8%,...
2026-01-26 12:21 AM EST
ATTENTION BGIN Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 21, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Bgin Blockchain Limited ("Bgin Blockchain Limited") (NASDAQ: BGIN) concerning potential violations of the federal securities laws. Bgin released unaudited financial results on November 14, 2025, for the six months ended June 30, 2025, revealing that total revenue had declined roughly $96 million from the previous year, operating expenses increased 582.8%,...
2026-01-21 2:44 PM EST
INO Investor Notice: Levi & Korsinsky Investigates Inovio Pharmaceuticals, Inc. for Securities Law Violations
New York, New York--(Newsfile Corp. - January 21, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Inovio Pharmaceuticals, Inc. ("Inovio Pharmaceuticals, Inc.") (NASDAQ: INO) concerning potential violations of the federal securities laws. The U.S. Food and Drug Administration ("FDA") announced on December 29, 2025, it had accepted Inovio's Biologics License Application ("BLA") for INO-3107, a treatment for recurrent respiratory papillomatosis, on a...
2026-01-21 2:42 PM EST
Shareholders Alert: Investigation Into Wealthfront Corporation (WLTH) - Contact Levi & Korsinsky to Protect Your Rights
New York, New York--(Newsfile Corp. - January 21, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Wealthfront Corporation ("Wealthfront Corporation") (NASDAQ: WLTH) concerning potential violations of the federal securities laws. On January 13, 2026, Barron's reported that shares of Wealthpoint "dropped 14% Tuesday morning after the wealth management company reported quarterly earnings and provided data on Monday afternoon that showed some softening in...
2026-01-21 1:10 PM EST
TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 20, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Instil Bio, Inc. ("Instil Bio, Inc.") (NASDAQ: TIL) concerning potential violations of the federal securities laws. Instil issued a press release on January 6, 2026, announcing that Axion Bio, Inc. ("Axion"), an Instil subsidiary, "has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ....
2026-01-20 3:03 PM EST
Potential Securities Fraud: Levi & Korsinsky Investigates Rezolute, Inc. (RZLT)
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Rezolute, Inc. (NASDAQ: RZLT) ("Rezolute, Inc.") concerning potential violations of the federal securities laws. On December 11, 2025, before the market opened, Rezolute announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism. The company reported that the study did not meet its primary...
2026-01-19 12:47 AM EST
Ongoing Securities Investigation into Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive Therapeutics, Inc.") concerning potential violations of the federal securities laws. What Happened? On January 9, 2026, Aquestive announced it received a letter from the FDA, identifying deficiencies in its NDA application that preclude labeling discussions and post-market commitments for Anaphylm, for...
2026-01-19 12:43 AM EST
Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Galectin Therapeutics Inc. (NASDAQ: GALT) ("Galectin Therapeutics Inc.") concerning potential violations of the federal securities laws. Galectin issued a press release on December 19, 2025, "announc[ing] that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company's previously submitted...
2026-01-19 12:32 AM EST
Levi & Korsinsky Investigates Possible Securities Fraud by Corcept Therapeutics Incorporated (CORT)
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated (NASDAQ: CORT) ("Corcept Therapeutics Incorporated") concerning potential violations of the federal securities laws. What Happened? On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension...
2026-01-19 12:27 AM EST
Investigation Opened on Behalf of Ultragenyx Pharmaceutical Inc. (RARE) Shareholders - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx Pharmaceutical Inc.") concerning potential violations of the federal securities laws. What Happened? On December 29, 2025, Ultragenyx announced the results from both its Phase III Orbit and Cosmic studies, both focused on the effectiveness of setrusumab (UX143) in Osteogenesis Imperfecta. Both...
2026-01-19 12:25 AM EST
MREO Investor Notice: Levi & Korsinsky Investigates Mereo BioPharma Group plc for Securities Law Violations
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo BioPharma Group plc") concerning potential violations of the federal securities laws. On December 29, 2025, before the market opened, Mereo announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). The company reported that neither study failed to...
2026-01-19 12:13 AM EST
Lost Money on Apogee Enterprises, Inc. (APOG)? Contact Levi & Korsinsky About Investigation
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Apogee Enterprises, Inc. (NASDAQ: APOG) ("Apogee Enterprises, Inc.") concerning potential violations of the federal securities laws. On January 7, 2026, before the market opened, APOG published fiscal third quarter 2026 financial results highlighting the company's performance expectations for the coming years. APOG disclosed its gross margin decreased to...
2026-01-19 12:10 AM EST
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation
New York, New York--(Newsfile Corp. - January 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ: VNDA) concerning potential violations of the federal securities laws. Vanda issued a press release on January 8, 2026, "announc[ing] that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) concluding that the...
2026-01-15 11:27 AM EST
DLTH ACTIVE INVESTIGATION: Lost Money on Duluth Holdings Inc.? Contact Levi & Korsinsky Now
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Duluth Holdings Inc. ("Duluth Holdings Inc.") (NASDAQ: DLTH) concerning potential violations of the federal securities laws. Duluth issued a press release on December 16, 2025, announcing its financial results for the third quarter of 2025. Among other items, Duluth lowered its nets sales guidance to a range of $555 million to $565 million, down from...
2026-01-14 1:20 PM EST
Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning potential violations of the federal securities laws. On January 8, 2026, before the market opened, CorMedix published preliminary fourth quarter and full year 2025 results disclosing that its major revenue driver DefenCath would change its reimbursement policy change beginning on July 1, 2026....
2026-01-14 9:58 AM EST
Levi & Korsinsky Investigates Possible Securities Fraud by Aquestive Therapeutics, Inc. (AQST)
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws. What Happened? On January 9, 2026, Aquestive announced it received a letter from the FDA, identifying deficiencies in its NDA application that preclude labeling discussions and post-market commitments for Anaphylm, for...
2026-01-14 9:55 AM EST
Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Galectin Therapeutics Inc. ("Galectin Therapeutics Inc.") (NASDAQ: GALT) concerning potential violations of the federal securities laws. Galectin issued a press release on December 19, 2025, "announc[ing] that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company's previously submitted...
2026-01-14 9:51 AM EST
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Ultragenyx Pharmaceutical Inc. (RARE)
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. ("Ultragenyx Pharmaceutical Inc.") (NASDAQ: RARE) concerning potential violations of the federal securities laws. What Happened? On December 29, 2025, Ultragenyx announced the results from both its Phase III Orbit and Cosmic studies, both focused on the effectiveness of setrusumab (UX143) in Osteogenesis Imperfecta. Both...
2026-01-14 9:48 AM EST
Investors in AST SpaceMobile, Inc. (ASTS) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into AST SpaceMobile, Inc. ("AST SpaceMobile, Inc.") (NASDAQ: ASTS) concerning potential violations of the federal securities laws. On December 15, 2025, it was revealed that AST's launch of its BlueBird 6 was delayed. The launch, which was scheduled for December 15, 2025, was tentatively pushed back to December 21, 2025. AST's BlueBird 6, the Company's...
2026-01-14 9:45 AM EST